Full Press Release Details
Announces First Quarter 2023 Results
Reiterates 2023 Revenue Guidance of $500-$510 million and Adjusted EBITDA1 Guidance of $45-$50 million
YORK, NY, May 8th, 2023 - DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services today announced
financial and operating results for the quarter ended March 31, 2023.
2023 Financial Highlights
Corporate Highlights
Capone, Chief Executive Officer of DocGo, commented, "We are very pleased with our continued operational execution, increase in
backlog and growth in our RFP channel during the quarter. In addition, we recently signed agreements to make our remote
patient monitoring, chronic care management and mobile urgent care services available to a major kidney care company, a large durable
medical equipment provider and numerous large cardiology practices. These agreements are expected to provide us with access to large
pools of qualified Remote Patient Monitoring and Chronic Care Management patients for whom DocGo is uniquely designed to service remotely,
driving down payor costs and improving patient outcomes. We believe that the total addressable market opportunity is substantial,
and we are excited to roll out these offerings over the remainder of the year."
Rosenberg, Chief Financial Officer of DocGo, added, "As expected, we continued to see gross margin pressure in the early part of
the first quarter related to startup costs associated with new projects. However, we saw improving margins as the quarter progressed,
as our rapid normalization initiatives started to take hold. This gives us confidence in our forecast for sequentially improving quarterly
gross margins over the remainder of 2023. Over the past 60 days, we have seen improvements in all of the key focus areas, such as staffing
agency labor utilization, overtime rates and rental vehicles. We expect the first phase of our rapid normalization project to be completed
by the end of July. Collectively, we expect these measures to help the Company reach our target of a 37% gross margin as we exit 2023."
call and webcast details:
access the Call me feature, which avoids the need to wait for an operator, click here.
webcast can be accessed under Events on the Investors section of the Company's website, https://ir.docgo.com/.
is a leading provider of last-mile mobile health services. DocGo is disrupting the traditional four-wall healthcare system by providing
care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals
elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers.
With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment in the comfort of
a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between
physical and virtual care. For more information, please visit www.docgo.com.
announcement contains forward-looking statements (including within the meaning of Section 21E of the U.S. Securities Exchange Act of
1934, as amended, and Section 27A of the U.S. Securities Act of 1933, as amended) concerning DocGo. These statements include, but are
not limited to, statements that address our expected future business and financial performance and statements about (i) our plans, objectives
and intentions with respect to future operations, services and products, including our transition to non-COVID related services, geographic
expansion, rapid normalization initiative, new and existing contracts, M&A activity, workforce growth, leadership transition, cash
position and share repurchase program, (ii) our competitive position and opportunities, including our addressable market opportunities
and our ability to realize the benefits from our operating model, and (iii) other statements identified by words such as "may",
"will", "expect", "intend", "plan", "potential", "believe", "seek",
"could", "estimate", "judgment", "targeting", "should", "anticipate", "predict"
"project", "aim", "goal", "outlook", "guidance", "design" and similar words,
phrases or expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as assumptions
made by, and information currently available to, management, and current market trends and conditions. Forward-looking statements inherently
involve risks and uncertainties, many of which are beyond our control, and which may cause actual results to differ materially from those
contained in our forward-looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties
that could materially affect current or future results include possible accounting adjustments made in the process of finalizing reported
financial results; any risks associated with global economic conditions and concerns; the effects of global outbreaks of pandemics or
contagious diseases or fear of such outbreaks, such as the COVID-19 coronavirus pandemic; competitive pressures; pricing declines; rates
of growth in our target markets; our ability to improve gross margins; cost-containment measures; legislative and regulatory actions;
the impact of legal proceedings and compliance risks; the impact on our business and reputation in the event of information technology
system failures, network disruptions, cyber-attacks, or losses or unauthorized access to, or release of, confidential information; and
the ability of the Company to comply with laws and regulations regarding data privacy and protection. We undertake no intent or obligation
to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise.
following information provides definition and reconciliation of the non-GAAP financial measure presented in this earnings release to
the most directly comparable financial measure calculated and presented in accordance with generally accepted accounting principles (GAAP).
The Company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information
supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance
with GAAP. Such non-GAAP financial measure should not be considered superior to, as a substitute for or alternative to, and should be
considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measure in this
earnings release may differ from similarly titled measures used by other companies.
EBITDA is considered a non-GAAP financial measure under the Securities and Exchange Commission's ("SEC") rules because
it excludes certain amounts included in net income (loss) calculated in accordance with GAAP. Specifically, Adjusted EBITDA is arrived
at by taking reported GAAP Net Income and adding back the following items: net interest expense/ (income), Provision/(benefit) for income
taxes, depreciation and amortization, other (income)/expense, non-cash equity-based compensation and certain other non-recurring expenses
consisting of expenses incurred in relation to the Company's merger with Motion in 2021, certain one-time legal settlements and
certain one-time expenses incurred in connection with acquisitions, beyond those that are typically incurred. The Company's management
believes that its Adjusted EBITDA measure is useful in evaluating DocGo's operating performance, as the calculation of this measure
generally eliminates the effect of financing and income taxes and the accounting effects of capital spending and acquisitions, as well
as other items of a non-recurring and/or non-cash nature. Adjusted EBITDA is not intended to be a measure of GAAP cash flow, as this
measure does not consider certain cash based expenses, such as payments for taxes or debt service. Management believes that using Adjusted
EBITDA in conjunction with GAAP measures such as net income assists investors in getting a more complete picture of the Company's
financial results and operations, affording them with a more complete view of what management considers to be the Company's core
operating performance as well as offering the ability to assess such performance as compared with that of prior periods and management's
public guidance. While many companies use Adjusted EBITDA as a performance measure, not all companies use identical calculations for
determining Adjusted EBITDA. As such, DocGo's presentation of Adjusted EBITDA might not be comparable to similarly titled measures
table below reflects the reconciliation of Net Income (Loss) to Adjusted EBITDA for the three ended March 31, 2022 compared to the same
period in 2022 (in millions):
| (in millions) | Q1 | |||||||
| 2022 | 2023 | |||||||
| Net Income/(loss) (GAAP) | $ | 9.4 | $ | (3.9 | ) | |||
| (+) Net Interest expense/ (income) | $ | 0.1 | $ | (0.8 | ) | |||
| (+) Income Tax | $ | 0.4 | $ | (2.1 | ) | |||
| (+) Depreciation & amortization | $ | 2.2 | $ | 3.6 | ||||
| (+) Other (income)/expense | $ | 0.1 | $ | (0.1 | ) | |||
| EBITDA | $ | 12.2 | $ | (3.3 | ) | |||
| (+) Non-cash stock compensation | $ | 1.4 | $ | 8.5 | ||||
| (+) Non-recurring expense | $ | 0.0 | $ | 0.4 | ||||
| Adjusted EBITDA | $ | 13.6 | $ | 5.6 |
DocGo Inc. and Subsidiaries
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Unaudited | Audited | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 120,056,897 | $ | 157,335,323 | ||||
| Accounts receivable, net of allowance of $3,780,545 and $7,818,702 as of March 31, 2023 and December 31, 2022, respectively | 131,599,567 | 102,995,397 | ||||||
| Assets held for sale | - | 4,480,344 | ||||||
| Prepaid expenses and other current assets | 6,737,378 | 6,269,841 | ||||||
| Total current assets | 258,393,842 | 271,080,905 | ||||||
| Property and equipment, net | 21,729,460 | 21,258,175 | ||||||
| Intangibles, net | 38,939,054 | 22,969,246 | ||||||
| Goodwill | 47,668,654 | 38,900,413 | ||||||
| Restricted cash | 7,461,821 | 6,773,751 | ||||||
| Operating lease right-of-use assets | 9,375,132 | 9,074,277 | ||||||
| Finance lease right-of-use assets | 9,170,429 | 9,039,663 | ||||||
| Equity method investment | 482,691 | 597,977 | ||||||
| Deferred tax assets | 10,973,522 | 9,957,967 | ||||||
| Other assets | 3,350,571 | 3,625,254 | ||||||
| Total assets | $ | 407,545,176 | $ | 393,277,628 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 19,028,065 | $ | 21,582,866 | ||||
| Accrued liabilities | 30,544,082 | 31,573,031 | ||||||
| Notes payable, current | 649,808 | 664,913 | ||||||
| Due to seller | 27,198,044 | 26,244,133 | ||||||
| Contingent consideration | 26,428,272 | 10,555,540 | ||||||
| Operating lease liability, current | 2,353,383 | 2,325,024 | ||||||
| Liabilities held for sale | - | 4,480,344 | ||||||
| Finance lease liability, current | 2,773,029 | 2,732,639 | ||||||
| Total current liabilities | 108,974,683 | 100,158,490 | ||||||
| Notes payable, non-current | 1,272,415 | 1,236,601 | ||||||
| Operating lease liability, non-current | 7,315,226 | 7,040,982 | ||||||
| Finance lease liability, non-current | 6,061,828 | 5,914,164 | ||||||
| Total liabilities | 123,624,152 | 114,350,237 | ||||||
| Common stock ($0.0001 par value; 500,000,000 shares authorized as of March 31, 2023 and December 31,2022; 102,932,174 and 102,411,162 shares issued and outstanding as of March 31, 2023 and December 31,2022, respectively) | 10,293 | 10,241 | ||||||
| Additional paid-in-capital | 310,049,864 | 301,451,435 | ||||||
| Accumulated deficit | (32,367,602 | ) | (28,972,216 | ) | ||||
| Accumulated other comprehensive gain | 984,864 | 741,206 | ||||||
| Total stockholders' equity attributable to DocGo Inc. and Subsidiaries | 278,677,419 | 273,230,666 | ||||||
| Noncontrolling interests | 5,243,605 | 5,696,725 | ||||||
| Total stockholders' equity | 283,921,024 | 278,927,391 | ||||||
| Total liabilities and stockholders' equity | $ | 407,545,176 | $ | 393,277,628 |
DocGo Inc. and Subsidiaries
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
COMPREHENSIVE (LOSS) INCOME
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenue, net | $ | 113,002,703 | $ | 117,891,552 | ||||
| Expenses: | ||||||||
| Cost of revenues (exclusive of depreciation and amortization, which is shown separately below) | 81,226,498 | 77,987,573 | ||||||
| Operating expenses: | ||||||||
| General and administrative | 29,220,317 | 23,860,616 | ||||||
| Depreciation and amortization | 3,649,329 | 2,201,021 | ||||||
| Legal and regulatory | 3,638,321 | 1,347,983 | ||||||
| Technology and development | 1,863,579 | 1,141,833 | ||||||
| Sales, advertising and marketing | 307,246 | 1,257,961 | ||||||
| Total expenses | 119,905,290 | 107,796,987 | ||||||
| (Loss) Income from operations | (6,902,587 | ) | 10,094,565 | |||||
| Other income (expenses): | ||||||||
| Interest income (expense), net | 809,172 | (135,606 | ) | |||||
| Loss on remeasurement of warrant liabilities | - | (58,749 | ) | |||||
| Loss on equity method investments | (115,286 | ) | (83,341 | ) | ||||
| Loss on disposal of fixed assets | (54,839 | ) | - | |||||
| Other income (expense) | 214,880 | (4,253 | ) | |||||
| Total other income (loss) | 853,927 | (281,949 | ) | |||||
| Net (loss) income before income tax benefit (expense) | (6,048,660 | ) | 9,812,616 | |||||
| Income tax benefit (provision) | 2,129,870 | (440,179 | ) | |||||
| Net (loss) income | (3,918,790 | ) | 9,372,437 | |||||
| Net (loss) income attributable to noncontrolling interests | (453,120 | ) | (1,257,257 | ) | ||||
| Net (loss) income attributable to stockholders of DocGo Inc. and Subsidiaries | (3,465,670 | ) | 10,629,694 | |||||
| Other comprehensive (loss) income | ||||||||
| Foreign currency translation adjustment | 243,658 | (5,863 | ) | |||||
| Total comprehensive (loss) income | $ | (3,222,012 | ) | $ | 10,623,831 | |||
| Net (loss) income per share attributable to DocGo Inc. and Subsidiaries - Basic | $ | (0.03 | ) | $ | 0.11 | |||
| Weighted-average shares outstanding - Basic | 102,579,291 | 100,177,082 | ||||||
| Net (loss) income per share attributable to DocGo Inc. and Subsidiaries - Diluted | $ | (0.03 | ) | $ | 0.09 | |||
| Weighted-average shares outstanding - Diluted | 102,579,291 | 115,652,049 |
DocGo Inc. and Subsidiaries
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net (loss) income | $ | (3,918,790 | ) | $ | 9,372,437 | |||
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | ||||||||
| Depreciation of property and equipment | 1,482,610 | 711,878 | ||||||
| Amortization of intangible assets | 1,365,636 | 633,363 | ||||||
| Amortization of finance lease right-of-use assets | 801,083 | 855,781 | ||||||
| Loss on disposal of assets | 54,839 | - | ||||||
| Deferred tax asset | (1,015,555 | ) | - | |||||
| Loss on equity method investment | 115,286 | 68,995 | ||||||
| Bad debt expense | (1,902,587 | ) | 1,154,235 | |||||
| Stock based compensation | 8,450,016 | 1,422,937 | ||||||
| Loss on remeasurement of warrant liabilities | - | (58,749 | ) | |||||
| Gain on liquidation of business | 70,284 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (24,668,050 | ) | 1,061,709 | |||||
| Prepaid expenses and other current assets | (174,059 | ) | (1,537,550 | ) | ||||
| Other assets | 274,683 | 2,188,242 | ||||||
| Accounts payable | (2,581,796 | ) | (671,744 | ) | ||||
| Accrued liabilities | (1,471,551 | ) | 3,063,148 | |||||
| Net cash (used in) provided by operating activities | (23,117,951 | ) | 18,264,682 | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Acquisition of property and equipment | (1,976,075 | ) | (602,416 | ) | ||||
| Acquisition of intangibles | (1,405,444 | ) | (534,624 | ) | ||||
| Acquisition of businesses | 1,574,604 | - | ||||||
| Proceeds from disposal of property and equipment | 117,420 | - | ||||||
| Net cash used in investing activities | (1,689,495 | ) | (1,137,040 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from revolving credit line | - | 1,000,000 | ||||||
| Repayments of notes payable | (129,370 | ) | (138,151 | ) | ||||
| Due to seller | (11,494,549 | ) | (160,250 | ) | ||||
| Noncontrolling interest contributions | - | 2,063,000 | ||||||
| Proceeds from exercise of stock options | 416,890 | 374,344 | ||||||
| Equity costs | - | (19,570 | ) | |||||
| Payments on obligations under finance lease | (744,030 | ) | (622,575 | ) | ||||
| Net cash (used in) provided by financing activities | (11,951,059 | ) | 2,496,798 | |||||
| Effect of exchange rate changes on cash and cash equivalents | 168,149 | (5,863 | ) | |||||
| Net (decrease) increase in cash and restricted cash | (36,590,356 | ) | 19,618,577 | |||||
| Cash and restricted cash at beginning of period | 164,109,074 | 179,105,730 | ||||||
| Cash and restricted cash at end of period | $ | 127,518,718 | $ | 198,724,307 |